Registry - Observational
The Ontario Registry of CHronic Myeloproliferative Neoplasms and Incident Cardiovascular Disease (ORCHID) / Inflammation in Myeloproliferative Philadelphia Chromosome Negative Neoplasms – Relationship with Biomarkers of Disease Activity (IMPACT) is a multi-centre prospective observational registry of patients with chronic myeloproliferative neoplasms (MPN) recruited within one year of diagnosis.
The registry’s goal is to inform the epidemiology and course of MPNs in the contemporary context.
Specifically, as MPN survival improves, and with the advent of treatments that may have cardiovascular adverse effects, there is a need to better understand the evolving epidemiology of MPNs.
The creation of this registry will inform the true incidence of vascular disease in the Tyrosine Kinase Inhibitors (TKI) treated Chronic Myeloid Leukemia (CML), Polycythemia vera (PV), Primary myelofibrosis (PMF) and Essential Thrombocytosis (ET) patient populations.
Registry - Observational
Darryl Leong is a Scientist at PHRI, Director of the McMaster University and Hamilton Health Sciences Cardio-Oncology Program, Associate Professor, Department of Medicine (Cardiology), McMaster University, and Staff Cardiologist at Hamilton Health Sciences. He has methodological expertise in clinical epidemiology and clinical trials, and content expertise in physical frailty, echocardiography, and cardio-oncology. His research is supported by the CIHR, and he has published more than 100 manuscripts including all the leading internal medical and cardiovascular journals.
He graduated from the University of Adelaide Medical School with Deans Listing and Honours for academic excellence, completed his cardiology training, Doctor of Philosophy, Master of Public Health, and Master of Biostatistics degrees at the University of Adelaide in Australia, and completed a post-doctorate fellowship in cardiovascular imaging at the Leiden University Medical Centre in The Netherlands, before re-locating to Canada.
Deborah Siegal is Assistant Professor, Division of Hematology and Thromboembolism, McMaster University, and an Associate Scientist in the Thrombosis program at PHRI, having transitioned from her role as a Scientist at PHRI to working at the Ottawa Hospital Research Institute. Her primary research interests include: improving patient outcomes after anticoagulant-related bleeding; emergency management of anticoagulants for acute bleeding or urgent surgery; understanding the factors that influence patient and physician decision-making after anticoagulant-related bleeding; and reducing red blood cell transfusion by minimizing iatrogenic blood loss for laboratory testing. She has expertise in the design and conduct of pragmatic cluster randomized trials, individual patient randomized trials, mixed-methods studies, observational studies, and meta-analyses.
She has received peer-reviewed grant support as principal investigator from the American Society of Hematology, CanVECTOR/Heart and Stroke Foundation of Canada, Ontario AFP Innovation Fund, and Hamilton Health Sciences Foundation. She has published over 60 articles in high-impact peer-reviewed journals including The New England Journal of Medicine. Deborah graduated from Queen’s University School of Medicine in 2009, and completed Internal Medicine and Hematology training at McMaster University. She holds Master of Science degrees in Pharmacology (University of Toronto) and Health Research Methodology (McMaster University).
Sumathy Rangarajan has been Program Director, Global Health, since 2016, preceded by many years’ service at PHRI in other roles. She oversees the PURE study team, as well as the INVICTUS rheumatic AF treatment trial, the CANPWR pediatric weight management registry, and others.
She holds both a Bachelor of Science Degree and a Master of Science degree from Pune University in India.
Back To Top